Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002217 · ClinicalTrials.gov registry record · NA
A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002217: Completed NA study, sponsored by Glaxo Wellcome.
NCT00002217 is a NA study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002217, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.
Interventions
- DRUG Lamivudine/Zidovudine
- DRUG Abacavir sulfate
- DRUG Amprenavir
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002217 record still lists
NCT00002217 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which Lamivudine/Zidovudine is the first listed.
NCT00002217 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002217 about?
NCT00002217 is a clinical study titled "A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs". The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.
What is the current status of trial NCT00002217?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002217?
The interventions under investigation include: Lamivudine/Zidovudine (DRUG), Abacavir sulfate (DRUG), Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002217?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.